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Estriol Bound and Ligand-free Structures
of Sterol 14-Demethylase
kingdoms from bacteria to animals and could be the
most ancient family of cytochrome P450 monooxygen-
ases (P450) (Aoyama et al., 1996). Being a key enzyme
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6611 Dumbarton Circle antifungal agents. Antifungal efficacy of azoles is attrib-
uted to their greater affinity for fungal CYP51 than forFremont, California 94555
the mammalian enzyme (Koltin and Hitchcock, 1997).
Use of standard antifungal therapies is limited for a num-
ber of reasons, including toxicity, low efficacy rates, andSummary
drug resistance, forcing the development not only of
new triazole agents with enhanced potency, but alsoSterol 14-demethylases (CYP51) are essential en-
the introduction of new classes of antifungal drugszymes in sterol biosynthesis in eukaryotes and drug
(Gupta and Tomas, 2003).targets in antifungal therapy. Here, we report CYP51
The occasional presence of sterols in bacteria isstructures in ligand-free and estriol bound forms. Us-
poorly understood. Sterol production by bacteria hasing estriol as a probe, we determined orientation of the
been demonstrated in three groups of prokaryotes,substrate in the active site, elucidated protein contacts
Methylococcales (Bird et al., 1971; Schouten et al.,with the invariant 3-hydroxy group of a sterol, and
2000), Myxobacteriales (Bode et al., 2003; Kohl et al.,identified F78 as a key discriminator between 4-methyl-
1983), and planctomycete Gemmata obscuriglobusated and 4,-dimethylated substrates. Analysis of
(Pearson et al., 2003). Mycobacterium tuberculosis doesCYP51 dynamics revealed that the C helix undergoes
not use sterols to build its cell envelope (Brennan andhelix-coil transition upon binding and dissociation of
Nikaido, 1995), and it is not known to produce sterols,a ligand. Loss of helical structure of the C helix in the
which is not surprising since squalene monooxygenaseligand-free form results in an unprecedented opening
and oxidosqualene cyclase, required to form the initialof the substrate binding site. Upon binding of estriol,
sterol, are absent in the M. tuberculosis genome. How-the BC loop loses contacts with molecular surface and
ever, the M. tuberculosis genome encodes a CYP51-tends to adopt a closed conformation. A mechanism
like P450 having a sequence identity of 29%–39% withfor azole resistance in the yeast pathogen Candida
CYP51 genes in animals, plants, and fungi (Aoyama etalbicans associated with mutations in the ERG11 gene
al., 1998) and 49% identity with CYP51 from the proteo-encoding CYP51 is suggested based on CYP51 protein
bacterium Methylococcus capsulatus (Jackson et al.,dynamics.
2002), in which sterol biosynthesis is known (Bird et al.,
1971). A CYP51-like gene was also identified in other
Introduction pathogens from genus Mycobacterium, including Myco-
bacterium avium and Mycobacterium bovis, and in the
Sterol biosynthesis is primarily a eukaryotic process and nonpathogenic species Mycobacterium smegmatis. An
is almost completely absent in prokaryotes. Essentially aromatic-degrading bacterium from deep-terrestrial-sub-
all eukaryotic cells use steroids in order to control the surface sediments, Novosphingobium aromaticivorans,
fluidity and flexibility of their cell membranes (Ourisson also contains a CYP51-like gene.
and Nakatani, 1994), and many cells use them as precur- The crystal structure of MTCYP51 was determined for
sors of hormones and other biologically active com- azole inhibitor bound forms (Podust et al., 2001a) and
pounds. The committed biosynthesis of steroids starts has remained the only structure for this important family
from squalene, a linear precursor that in the first step of enzymes. Eukaryotic CYP51s are membrane associ-
undergoes epoxidation catalyzed by squalene monoox- ated proteins and represent a challenge for structural
ygenase. Cyclization of squalene epoxide to form the and biophysical characterization. The MTCYP51 struc-
initial sterol proceeds through the action of oxidosqua- ture revealed a most unusually shaped P450. Wide-open
lene cyclase. A variety of further reactions lead to differ- access to the active site is created by the disrupted and
ent cyclic triterpenes, such as lanosterol in yeast and bent I helix and extended conformation of the BC loop.
animals, eburicol in filamentous fungi, and obtusifoliol The structure also revealed a binding mode for azole
in plants. All are substrates in the next step of the sterol inhibitors 4-phenylimidazole and the clinically important
biosynthetic pathway, oxidative removal of the 14-methyl fluconazole, although the natural substrate binding
group by cytochrome P450 sterol 14-demethylase mode has remained obscure.
(CYP51), which leads to membrane sterols in animals (cho- Current research is aimed at elucidation of specificity
lesterol), fungi (ergosterol), and plants (phytosterols). of substrate binding in the CYP51 family. Since structural
CYP51 is widely distributed throughout all biological differences between substrates undergoing 14-demeth-
ylation are small and local, the difference in substrate
specificity is likely caused by only a few amino acid*Correspondence: larissa.m.podust@vanderbilt.edu
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Figure 1. Analysis of MTCYP51 by SDS-PAGE
Analysis by SDS-PAGE of E. coli-expressed MTCYP51, wild-type
and mutants, upon nonreducing and reducing conditions.
differences in the substrate-recognition site. In the cur-
rent study, estriol was used as a probe for the substrate
binding site of MTCYP51. The estriol bound 1.5 A˚
MTCYP51 structure unequivocally defined the orienta-
tion of the sterol in the active site. It also established
that residue F78 is a key discriminator between CYP51
substrates that are singly versus doubly methylated at
position C-4. The ligand-free 2.0 A˚ MTCYP51 structure
revealed a further opening from the protein surface to
the heme due to helix-coil transition in the C helix. Com-
parison of estriol bound and ligand-free forms of
MTCYP51 indicates that binding of estriol in the active
site induces remodeling of the C helix and the BC loop,
which tend to enclose the sterol within the active site.
The dynamics of MTCYP51 provide insights into the
molecular basis of the mechanism of azole resistance
in the yeast pathogen Candida albicans due to muta-
tions in the CYP51 drug target.
Results and Discussion
Figure 2. Analysis of MTCYP51 Tryptic Digests by SELDI-TOF MassProtein Design
Spectrometry
Analysis by SDS-PAGE of MTCYP51 after purification
(A and B) Localization of the DTT-sensitive MTCYP51 tryptic digest
from an Escherichia coli expression system revealed peaks corresponding to (A) the crosslinks between MTCYP51 tryptic
that in nonreducing conditions the protein migrates as peptides containing cysteine residues, and (B) the C442-containing
a number of conformers of different mobility (Figure 1). tryptic fragment showing a doubling in peak intensity upon reduction.
(C) Theoretical masses of MTCYP51 tryptic fragments containingThis effect diminishes and disappears with increasing
cysteine, and calculated and experimental (in parentheses) massesconcentrations of DTT in the sample buffer, which ap-
for disulfide crosslinks.parently breaks intramolecular disulfide bonds formed
between cysteine residues in MTCYP51. Since no disul-
fide bonds are present in folded MTCYP51 (Podust et and spontaneous formation of disulfide bonds. The mis-
folded portion of MTCYP51 copurifies with the correctlyal., 2001a), it is assumed that their formation occurs as
a result of misfolding of a fraction of the protein during folded protein through all three chromatographic steps.
Analysis of tryptic digests of purified MTCYP51 byheterologous expression. As has been shown earlier
(Lepesheva et al., 2001), folding of MTCYP51 in E. coli SELDI-TOF mass spectrometry showed four major DTT-
sensitive peaks (Figure 2A), each corresponding to adoes not occur until almost the entire coding sequence
is translated. Although not investigated in the current putative sum of two predicted tryptic fragments con-
taining cysteine (Figure 2C). Interpretation of masses forwork, MTCYP51 might fold in E. coli via a path promoted
by chaperonins GroEL/S (Houry et al., 1999). Proteins DTT-sensitive ions leads to the conclusion that three of
the four peaks contain the 1314.62 Da fragment withfollowing this pathway fold slowly and are prone to ag-
gregation (Gottesman and Hendrickson, 2000). Slow cysteine at position 442 (C442), including intermolecular
crosslinking between two C442-containing fragments.folding with formation of aggregates would allow cys-
teine residues to interact with each other with random Intensity of the peak corresponding to the C442 frag-
Probing CYP51 Active Site with a Substrate Analog
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Table 1. Summary of Crystallographic Statistics
Crystal Ligand-free Estriol Bound
Space group P212121 P212121
Unit cell 46.49/84.83/110.03 47.16/84.52/110.81
Data Collection
Wavelength 1.5418 1.0000
Resolution (A˚)a 40–2.05 (2.12–2.05) 50–1.55 (1.61–1.55)
Total/unique observations 103,288/25,277 264,701/63,041
Completeness (%) 90.6 (90.9) 96.7 (85.3)
Average I/ 10.6 (3.1) 31.6 (3.0)
Redundancy 4.1 (3.1) 4.2 (3.2)
Rsymb 0.105 (0.457) 0.073 (0.37)
Refinement Statistics
Rcrys/Rfree (%)c 18.5/23.6 20.6/22.7
Rms deviation
Bonds (A˚) 0.006 0.006
Angles () 1.2 1.2
Model Statistics
Protein atoms 3437 3418
Ligand atoms 43 85
Solvent molecules 280 323
Ramachandran (%)d 90.1/9.7/0.3 92.2/7.5/0.3
a Values for highest-resolution shells are in parentheses.
b Rsym  |Ii  I|/I, in which I is the mean intensity of reflection.
c Rcryst  ||F0|  |Fc||/|F0|, calculated with the working reflection set. Rfree is the same as Rcryst but calculated with the reserved reflection set.
d Program PROCHECK (Laskowski et al., 1993).
ment itself increases approximately 2-fold upon DTT MTCYP51 during heterologous expression and folding
are nonspecific and might be a result of overloading oftreatment (Figure 2B), suggesting that about half of the
total C442 cysteine residues in the protein preparation the E. coli molecular chaperone machinery. Work on
crystallization and improvement of the protein constructare involved in Cys-Cys bridge formation, which coin-
cides with the fraction of the protein containing heme developed in parallel. Therefore, the ligand-free crystals
were obtained from the wild-type, and estriol boundin the P450 form as estimated by heme content assay
(not shown). These facts lead to the conclusion that crystals were obtained from the C37L/C442A-MTCYP51
double mutant a few years later (Table 1).crosslinked misfolded protein species do not incorpo-
rate heme, and thus only half of the protein in the prepa-
ration is folded properly, resulting in inconsistency in Estriol as a Probe for CYP51 Substrate
Binding Sitecrystal growth from one protein batch to another and
failure in obtaining sterol bound crystals. To eliminate or The first attempts to cocrystallize MTCYP51 with the
substrate lanosterol encountered two major problems:at least to reduce this effect, three of the four MTCYP51
cysteines, C37, C151, and C442, were mutated to leu- highly insoluble lanosterol and inconsistency in crystal
growth from one protein batch to another. These at-cine, threonine, and alanine, respectively. These substi-
tutions were chosen empirically by expression of mu- tempts resulted in ligand-free crystals and failure to ob-
tain crystals of the substrate bound form. To addresstated species followed by recording of CO-reduced
difference spectra and monitoring of absorbance at the first problem, a number of more soluble sterols were
tested in spectral protein binding assays. A few of them,450 nm. Mutants showing more abundant expression
based on this criterion were selected. C151 is the most estriol, androstenolone, and androstenedione, were
found to bind to MTCYP51 with reasonable affinity, gen-sensitive of these three positions for mutagenesis, since
its substitution to alanine, leucine, or serine resulted in erating normal type I spectra characteristic of P450 sub-
strate binding (Figure 3A). Estriol, having affinity of 100complete or almost complete loss of absorption at
450 nm. 	M versus 200 	M for androstenolone and androstene-
dione, was chosen as a probe for cocrystallization withOn SDS-PAGE, the C442A-MTCYP51 single mutant
at nonreducing conditions migrates similar to the wild- MTCYP51. Estriol is not metabolized by MTCYP51 be-
cause of lack of the 14-methyl group. Estriol also doestype (Figure 1), as multiple bands with different mobility,
while the C37L/C442A-MTCYP51 double mutant shows not have methyl groups at positions C-4, C-10, and C-13,
nor an aliphatic side chain at C-17. Instead, it is hydroxyl-only one DTT-sensitive conformer, which apparently
corresponds to a single crosslink between the two re- ated at C-16 and C-17, which makes it far more soluble
then lanosterol and other CYP51 substrates (Figure 3B).maining cysteines in the protein sequence. The C37L/
C151T/C442A-MTCYP51 triple mutant migrates as a sin- Additionally, estriol ring planarity is altered compared
to substrates due to different localization of the doublegle band independent of the presence of DTT. This ob-
servation indicates that disulfide bonds formed in bond(s). Taken together, these differences indicate that
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closed at the surface. The ligand-free MTCYP51 struc-
ture determined in the current work revealed a surprising
feature that has not previously been observed in P450s.
In the ligand-free state, the C helix of MTCYP51 is disor-
dered and no electron density is observed for residues
91–100. Although this helix is known to shift significantly
in P4502B4 upon inhibitor binding (Scott et al., 2004),
all large-scale conformational changes in P4502B4 are
due to the relocation of structural elements toward each
other with, according to the authors, remarkably little
remodeling at the secondary structure level. Absence
of the electron density for the C helix in the ligand-free
MTCYP51 appears as a further opening of the heme
binding pocket (Figure 4A). In contrast, in the 4-phenyl-
imidazole bound structure, the C helix is well defined
(Figure 4B), although temperature factors of residues
constituting the helix are among the highest in the mole-
cule (Figure 4C). Substitution of 4-phenylimidazole with
fluconazole results in loss of the C helix helical structure,
although continuous electron density persists.
Remodeling of the C Helix in MTCYP51
upon Ligand Binding
Interestingly, two estriol molecules are bound per one
molecule of protein in the MTCYP51 structure. One is
bound in the active site, while another binds in the hy-
drophobic crevice on the protein surface formed by the
C and the H helices and the N terminus of the I helix,
close to the active site entrance (Figure 4A), via purely
hydrophobic interactions. Currently, it is impossible to
distinguish whether binding of the second sterol mole-
Figure 3. Estriol Binding by MTCYP51 cule would have functional meaning or is an artifact of
(A) Type I binding spectra resulting from MTCYP51 titration with crystallization and crystal packing, since its contacts
increasing concentrations of estriol ranging from 50 to 250 	M and with the symmetrically related protein molecule are quite
linearization of the titration data. extensive.(B) Endogenous CYP51 substrates. Steroid carbon nomenclature is
Analysis of the MTCYP51 structure in its estriol boundshown for lanosterol.
form supports our previous assumption that MTCYP51
undergoes conformational changes upon binding of
substrate in the active site (Podust et al., 2001a; Podustthe estriol binding mode would not be exactly the same
as that for a more physiologic substrate; however, it et al., 2001b). In the ligand-free form, the C helix and the
C-terminal part of the BC loop are disordered. Binding ofdoes allow us to address issues such as (1) substrate
orientation in the active site, (2) protein contacts with azole inhibitors or estriol triggers ordering of the C helix
in the 4-phenylimidazole bound form (Figure 4B) andthe invariant 3
-hydroxy group, and (3) the substrate
selectivity in the CYP51 family toward discrimination partial ordering in fluconazole- and estriol bound forms
(Figures 4A and 4B). Estriol binding restores one helicalbetween 4-methylated and 4,
-dimethylated sub-
strates. turn of the C helix. As a result of this transition, in the
ligand-free form one of the heme propionates becomes
exposed to the surface rather than being buried withinLigand-free Structure
A prevailing view on substrate binding by cytochrome the protein interior. Binding of azole inhibitors does not
affect conformation of the BC loop. It remains stretchedP450 is that the F and G helices and the loop connecting
them undergo an open/close motion, which allows sub- over the protein surface in both ligand-free and inhibitor
bound forms. Binding of the estriol probe in the activestrate to enter and product to be released. A number of
bacterial CYPs (Park et al., 2002; Podust et al., 2003; site releases the BC loop from its position on the protein
surface. The BC loop tends to relocate; however, it neverYano et al., 2000; Zerbe et al., 2002) and mammalian
P4502B4 (Scott et al., 2003) demonstrate the wide range orders enough to build continuous electron density in
the estriol bound form, where the region 85–94 is repre-of openings available to the F-G region in P450s. How-
ever, flexibility of P450s seems not to be limited by the sented by scattered electron density.
Although estriol mimics certain features of CYP51dynamics of the F-G region. Sterol metabolizing CYP51
is another example of an accessible active site, where substrates, it lacks the aliphatic side chain at C-17,
which in this orientation of sterol in the active site wouldthe opening is generated by the break in the I helix and
the extended conformation of the BC loop stretched point toward the molecular surface, probably interacting
with the BC loop and the C helix. We predict that theseover the protein surface. Although the FG channel is
also apparent in the CYP51 structure, its entrance is interactions would allow the BC loop to adopt a function-
Probing CYP51 Active Site with a Substrate Analog
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Figure 4. Stereoviews of MTCYP51 Structure in Different Forms
(A and B) Superimposition of the (A) ligand-free (cyan) and estriol bound (rose) and (B) 4-phenylimidazome bound (gray) and fluconazole
bound (yellow) forms of the MTCYP51. Heme is shown in pink, estriol in green, and fluconazole in blue.
(C) Distribution of the estriol binding residues (green triangles) and mutations in azole-resistant clinical isolates of pathogen C. albicans (red
squares) along MTCYP51 sequence. Plot shows temperature factors averaged per residue as they are observed in the 4-phenylimidazole
bound form.
ally relevant closed conformation. Also, we assume that ria, methionine in low eukaryotes, leucine in yeast and
fungi, and phenylalanine in vertebrates (Figure 5).once substrate is bound in the active site, the guanidi-
nium group of R96 would create stacking interactions
with the unsaturated bond of the obtusifoliol side chain. Estriol Binding and Substrate Specificity in CYP51
Estriol enters the MTCYP51 active site apparently withSince CYP51 substrates are largely discriminated based
on the structure of sterol side chain, it is not a surprise its 3
-hydroxy group leading through the opening cre-
ated by the disordered C helix, bent I helix, and by thethat this residue in CYP51 isoforms, with few exceptions,
is phyla specific, being arginine in plant and most bacte- extended conformation of the BC loop, as was predicted
Structure
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the CYP51 family) (Figure 5). Only one residue, F78, is
specific for plant obtusifoliol-metabolizing CYP51s and
for other CYP51s whose preference for obtusifoliol ver-
sus 4,4
-dimethylated substrates was demonstrated
in vitro, namely for M. tuberculosis (Bellamine et al.,
1999) and Trypanosoma brucei (Lepesheva et al., 2004)
CYP51. F78 is also present in a number of CYP51 iso-
forms whose substrate preferences have not yet been
determined: M. avium, M. smegmatis, Trypanosoma vi-
vax, Leishmania major, Dictyostelium, and N. aromatici-
vorans. F78 is a leucine in all other known CYP51 or-
thologs, except for proteobacterium M. capsulatus and
low eukaryote Trypanosoma cruzi where it is an isoleu-
cine, and for two fungi species where this residue is
methionine. F78 is situated above the C-4 atom of estriol
within only 3.76 A˚ and would directly interfere with the
4
-methyl group in 4,4
-dimethylated CYP51 sub-
strates (Figure 6C). As such, F78 is a candidate to be a
key determinant of obtusifoliol selectivity in the CYP51
family. Thus, we would predict that all bacterial CYP51s
listed in Figure 5, with the exception of M. capsulatus,
would favor 4-methylated substrate obtusifoliol versus
4,4
-dimethylated substrates. Three out of four lower
eukaryote CYP51s, the exception being T. cruzi, should
also favor obtusifoliol.
Dynamics of CYP51 and Fluconazole Resistance
Estriol binds in the active site of MTCYP51 via the same
set of residues as fluconazole, plus I323 and M433 inter-
acting with the invariant 3
-hydroxy group. The move-
ment of the side chains in this portion of the substrate
binding site is minimal for all four MTCYP51 forms. Thus,
this part of the binding site is preformed before binding.
As has been discussed elsewhere (Podust et al., 2001a,
2001b), residues interacting with fluconazole in MTCYP51
do not overlap with the residues mutated in CYP51 in
Figure 5. Estriol-Interacting Residues across Phyla fluconazole-resistant strains of the most studied yeast
Fragments of multiple sequence alignment between 59 CYP51 iso- pathogen, C. albicans, with the exception of F83 (Figure
forms from different organisms representing residues binding estriol 4C). Instead, the majority of mutations identified in clini-
in MTCYP51, noted by closed circles at top. Alignment performed
cal isolates (Marichal et al., 1999; Morschhauser, 2002)using the MAP algorithm as implemented in the BCM Search
flank the most dynamic regions of the MTCYP51, the CLauncher (http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.
helix, the BC, and the GH loops. An exception is a muta-html).
tion hot spot associated with the N-terminal part of the
cysteinyl loop in the heme binding pocket, the hinge
between 
 sheet and -helical protein domains, whichbased on molecular dynamic simulations (Podust et al.,
2001b). Electron density for estriol is unambiguously is not the most dynamically active region in the molecule
(Figure 4C). Half of the C. albicans mutations mappeddefined (Figure 6B). The invariant 3
-hydroxy group of
estriol does not hydrogen bond to any side chains in to this hot spot are substitutions of glycine to serine or
glutamate, which should affect flexibility of the cysteinylthe active site, but instead is hydrogen bonded to the
carbonyl oxygen of M433 and via an ordered water mole- loop itself and probably interdomain conformational
changes, if the latter should occur upon binding of sub-cule to the amide nitrogen of I322 (Figure 6A). Addition-
ally, the carbonyl oxygen of I323 is within 4.26 A˚ from strate.
Comparison of ligand-free and ligand bound MTCYP51the invariant OH-group of estriol and may contribute in
a hydrogen bonding network either for estriol or for a structures indicates that remodeling of the C helix and
the BC loop are required to “close the lid” and completenatural substrate. Altogether, nine protein side chains
are within 4.0 A˚ from estriol: Y76, F78, F83, F255, A256, formation of the high-affinity substrate binding site of
MTCYP51. Failure to close the lid would result in re-H259, L321, M433, and R96. In addition, V434 and M79
are within 4.6 A˚ and might interact either with substrate duced affinity for the ligand. Considering a high level of
conservation of residues involved in substrate bindingmethyl group(s) at C-4 (V434) or at C-10 (M79). Three
(Y76, F83, and H259) of these eleven residues are invari- within each phylum (Figure 5), we conclude that organ-
isms cannot afford to change substrate-interacting resi-ant among all CYP51s (with the exception of N. aroma-
ticivorans, which so far is the most remote relative in dues in CYP51 to combat the effect of drugs without
Probing CYP51 Active Site with a Substrate Analog
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Figure 6. Estriol Binding in the Active Site of
MTCYP51
(A) Stereo view of estriol bound in the active
site of MTCYP51.
(B) Electron density for estriol represented by
a fragment of the 2Fo-Fc composite omit map
contoured at 1.2.
(C) Estriol and F78 are represented by their
van der Waals radii in the binding site of
MTCYP51, in the same orientations as in
stereo view (A).
Experimental Proceduresinterference in the physiological function of the enzyme,
sterol biosynthesis. What might be allowed, though, is
Protein Design, Purification, and Analysisto modulate protein dynamics through mutagenesis of
MTCYP51 differs from the wild-type protein by addition of a 4 His
residues in fulcrum positions, which are not involved tag at the C terminus. For cocrystallization with estriol, the double
directly in interactions with substrate but which affect mutant C37L/C442A-MTCYP51 was used. Both forms were ex-
pressed in HMS174(DE3) (Novagen) E. coli strain at 20C–25C withthe protein’s ability to perform required rearrangements,
an induction period of 20 hr. Purification on Ni2 resin (Qiagen) wasso that the lid does not close when an inhibitor binds,
followed by flow-through chromatography on S-Sepharose (Amer-maintaining the low-affinity state, but it does close in
sham Pharmacia Biotech) and binding to Q-Sepharose (Amershamresponse to substrate binding, leading to a higher-affin-
Pharmacia Biotech), from which MTCYP51 was eluted by NaCl gra-
ity state. We hypothesize that this is one of the mecha- dient, 0–0.5 M. Protein was concentrated to 0.8 mM by using a
nisms the pathogen C. albicans and probably other Centricon YM-50 centrifugal device.
Purified wild-type and mutant MTCYP51 were analyzed by SDS-pathogens use to favor substrate versus inhibitor.
PAGE in the absence and presence of DTT in increasing concentra-Clearly, the residual affinity to the drug cannot be de-
tions. 0.5 	g of protein in 50 	l of SDS-sample buffer containingcreased by this mechanism below a background value,
dithiothreitol (DTT), as indicated above each lane (Figure 1), waswhich is determined by the area of the preformed portion
incubated for 5 min at 95C. 3.5 	l from each sample was loaded
of the active site interacting with the drug. To combat onto 12.5% precast gels and run using the FastSystem (Amersham
infection more efficiently, one can increase the size of Pharmacia Biotech).
Heme content was estimated as a ratio between protein con-the inhibitor to cover a larger area. This approach has
taining heme with P450 nm absorbance and total protein. Concen-been utilized in development of second-generation anti-
tration of total protein was measured using the BCA Protein Assayfungal triazoles such as voriconazole, ravuconazole,
Reagent (Pierce) according to the protocol provided by the manufac-itraconazole, and posaconazole (Gupta and Tomas,
turer. Concentration of heme-containing protein was accessed by
2003), which are all larger than fluconazole. In particular, CO-reduced difference spectra based on the extinction coefficient
the long side chain of itraconazole and posaconazole of 91,000 M1cm1 (Omura and Sato, 1964).
is likely to extend into the FG channel within CYP51 to
provide additional interactions with the protein, as was Mass-Spectrometry Analysis of MTCYP51 Tryptic Digests
modeled elsewhere based on the structure of MTCYP51 8 	g of MTCYP51 was digested with trypsin (Roche) in 100 	l of 50
mM ammonium bicarbonate using an enzyme/substrate ratio of 1:40(Gollapudy et al., 2004; Xiao et al., 2004). However, this
(w/w) at 37C overnight. One-half of the tryptic digest was incubatedapproach to drug design is limited by the size of the
with 5 mM DTT for 20 min at 70C. 1 	l aliquots of the reduced andpreformed binding area itself. Another approach, which,
nonreduced tryptic digests were analyzed using a Protein Biology
based on our knowledge, has not yet been exploited in System II ProteinChip Reader, which is a surface-enhanced laser
antifungal drug design would be to mimic those sub- desorption/ionization time of flight (SELDI-TOF) mass spectrometer
strate-protein interactions that trigger conformational (Ciphergen Biosystems, Inc). -cyano-4-hydroxy-cinnamic acid was
used as the energy-adsorbing molecule, and the mass spectrometerchanges leading to the lid closure. Apparently, the ali-
was externally calibrated using an All-in-1 Peptide standard (Ci-phatic side chain of the substrate would provide part of
phergen Biosystems, Inc.). The experimental data were convertedthese interactions. The availability of a crystal structure
from m/z values and are reported as average molecular weights in
of a substrate bound MTCYP51 could help refine our Daltons.
understanding of the specific contacts required for
drugs to trigger the transition from the preformed lower-
Estriol Binding Assay
affinity binding site to the induced-fit higher-affinity one, Estriol, 1,3,5(10)-estratrien-3,16,17
-triol (Sigma)-induced spectral
which could push affinity of new drugs into a nanomolar shifts were monitored at room temperature using a Shimazu UV-
2401 spectrophotometer. Samples contained 5 	M MTCYP51 in 100range.
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mM Tris-HCl (pH 7.5), 10% glycerol. Estriol was dissolved in DMSO Bird, C.W., Lynch, J.M., Pirt, F.J., and Reid, W.W. (1971). Steroids
and squalene in Methylococcus capsulatus grown on methane. Na-at a stock concentration of 25 mM. Kd value was estimated using
spectrophotometric titration by adding estriol in 1 	l aliquots to the ture 230, 473–474.
sample and DMSO to the reference cuvette, followed by recording Bode, H.B., Zeggel, B., Silakowski, B., Wenzel, S.C., Reichenbach,
of difference spectra. Data were linearized in a S0/A versus S0 plot, H., and Muller, R. (2003). Steroid biosynthesis in prokaryotes: identi-
where S0 is a total concentration of estriol in the reaction mixture. fication of myxobacterial steroids and cloning of the first bacterial
2,3(S)-oxidosqualene cyclase from the myxobacterium Stigmatella
Crystal Growth and Data Collection aurantiaca. Mol. Microbiol. 47, 471–481.
Crystals were grown by vapor diffusion in a hanging drop, using 1:1 Brennan, P.J., and Nikaido, H. (1995). The envelope of Mycobacteria.
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Pannu, N.S. (1998). Crystallography and NMR system: a new soft-estriol bound crystals. Lanosterol or estriol dissolved in acetone or
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